Nine-Protein Risk Score May Help Predict CV Events in Stable CHD

This article originally appeared here.
Share this content:
Nine-Protein Risk Score May Help Predict CV Events in Stable CHD
Nine-Protein Risk Score May Help Predict CV Events in Stable CHD

WEDNESDAY, June 22, 2016 (HealthDay News) -- A nine-protein risk score may help predict cardiovascular events among patients with stable coronary heart disease (CHD), according to a study published in the June 21 issue of the Journal of the American Medical Association.

Peter Ganz, M.D., from the University of California, San Francisco, and colleagues conducted a prospective cohort study involving patients with stable CHD. They derived and validated a nine-protein risk score for four-year probability of myocardial infarction, stroke, heart failure, and all-cause death in a derivation cohort that included 938 samples and a validation cohort with 971 samples. The risk score was compared with the Framingham secondary event model, refit to the cohorts in this study.

The researchers found that the C statistics were 0.66, 0.74, and 0.75 for refit Framingham, nine-protein, and refit Framingham plus nine-protein models, respectively, in the discrimination cohort. The corresponding C statistics were 0.64, 0.70, and 0.71, in the validation cohort. Adding the nine-protein risk score to the refit Framingham correlated with a 0.09 and 0.05 increase in the C statistic in the derivation and validation cohorts, respectively. The integrated discrimination index for the nine-protein model compared with the refit Framingham model was 0.12 and 0.08 in the derivation and validation cohorts, respectively.

"Further research is needed to assess whether the score is more accurate in a lower-risk population," the authors write.

Several authors disclosed financial ties to SomaLogic, which provided funding for and execution of the protein assays.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »